| Identification | Back Directory | [Name]
SUN11602 | [CAS]
704869-38-5 | [Synonyms]
CS-2504
SUN11602
SUN11602;SUN11602
4-[[4-[[2-[(4-Amino-2,3,5,6-tetramethylphenyl)amino]acetyl]methylamino]-1-piperidinyl]methyl]benzamide | [Molecular Formula]
C26H37N5O2 | [MDL Number]
MFCD28133375 | [MOL File]
704869-38-5.mol | [Molecular Weight]
451.604 |
| Chemical Properties | Back Directory | [Boiling point ]
679.8±55.0 °C(Predicted) | [density ]
1.19±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: soluble | [form ]
A crystalline solid | [pka]
16.19±0.50(Predicted) | [color ]
Light yellow to yellow | [InChI]
1S/C26H37N5O2/c1-16-18(3)25(19(4)17(2)24(16)27)29-14-23(32)30(5)22-10-12-31(13-11-22)15-20-6-8-21(9-7-20)26(28)33/h6-9,22,29H,10-15,27H2,1-5H3,(H2,28,33) | [InChIKey]
KCODNOOPOPTZMO-UHFFFAOYSA-N | [SMILES]
N2(CCC(CC2)N(C)C(=O)CNc3c(c(c(c(c3C)C)N)C)C)Cc1ccc(cc1)C(=O)N |
| Hazard Information | Back Directory | [Uses]
SUN 11602 is a novel aniline compound, which mimics the neuroprotective mechanisms of basic fibroblast growth factor. | [Biological Activity]
SUN11602 is an orally active basic fibroblast growth factor (bFGFFGF2) mimetic th at protects against glutamate toxicity in primary r at cerebrocortical neuron (0.1-1 μM SUN11602; 150 μM glutamate) and murine hippocampal neuron cultures (0.3-3 μM SUN11602; 100 μM glutamate). When administered in vivoSUN11602 exhibits therapeutic efficacy in a r at hippocampal-lesion model (1-10 mg/kg p.o. 24h post Aβ1-40 injection) and a murine MPTP-induced nigrostriatal degeneration model (2.5-5 mg/kg/day p.o.). | [in vivo]
In WT mice, SUN11602 increases the levels of newly synthesized Calb in cerebrocortical neurons and suppresses the glutamate-induced rise in intracellular Ca2+. This Ca2+-capturing ability of Calb allows the neurons to survive severe toxic conditions of glutamate[1]. Oral administration of SUN11602 at the midpoint of Aβ1-40 and ibotenate injections attenuate short-term memory impairment in the Y-maze test, as well as spatial learning deficits in the water maze task. In addition, the SUN11602 treatment inhibits the increase of peripheral-type benzodiazepine-binding sites (PTBBS),which are a marker for gliosis[3]. |
|
|